Jie Wang

Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology

17 Pan-jia-yuan South Lane

Chaoyang District

Beijing

China

SCHOLARLY PAPERS

7

DOWNLOADS

336

TOTAL CITATIONS

4

Scholarly Papers (7)

1.

Immunotherapy Efficacy and Safety of Programmed Cell Death 1 (PD-1) versus Programmed Death Ligand-1 (PD-L1) Inhibitors in Pan-Cancer Patients: A Systematic Review and Meta-Analysis

Number of pages: 36 Posted: 12 May 2019
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, 3D Medicines, Inc., 3D Medicines, Inc., Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., 3D Medicines, Inc., Peking University - Department of Epidemiology and Biostatistics, 3D Medicines, Inc., Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 109 (515,258)
Citation 1

Abstract:

Loading...

2.

Real-World Treatment Patterns and Clinical Outcomes in EGFR-Mutant Unresectable Locally Advanced Lung Adenocarcinoma: A Multi-Center Cohort Study

Number of pages: 35 Posted: 03 Nov 2020
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Department of radiation oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Chinese Academy of Sciences (CAS) - Department of Radiation Oncology, Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Department of Oncology, Tongji Hospital,Tongji Medical University, Huazhong University of Science and Technology, Cancer Hospital of Shanxi Province, Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University, Department of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Hangzhou Cancer Hospital - Department of Radiation Oncology, Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Department of Radiation Oncology, Cangzhou Central Hospital, Fujian Provincial Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - Department of Radiation Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - Department of Radiation Oncology, Department of radiation oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College - Thoracic Surgery Department, Johns Hopkins University - Division of Biostatistics and Bioinformatics and Chinese Academy of Medical Sciences and Peking Union Medical College - Department of Radiation Oncology
Downloads 68 (684,636)

Abstract:

Loading...

EGFR mutation, Non small cell lung cancer, EGFR-TKI and radiotherapy, Local advanced

3.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (828,027)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

4.

The Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-Analysis

Number of pages: 20 Posted: 23 Dec 2020
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Burning Rock Biotech - The Medical Department, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 35 (911,525)

Abstract:

Loading...

Carcinoma, non-small-cell lung; tumor mutation burden, immune checkpoint inhibitors, predictive biomarker, meta-analysis

5.

Development and Validation of an Individualized Model for Predicting COVID-19 Deterioration in Patients with Cancer: A Multicenter Retrospective Study

Number of pages: 25 Posted: 20 Jul 2020
Wuhan University - Cancer Center, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Orthopedic Surgery, Wuhan University - Cancer Center, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Oncology, Hubei Provincial Hospital of Integrated Chinese & Western Medicine - Department of Oncology, Wuhan Fifth Hospital - Department of Oncology, Yangtze University - Department of Oncology, Wuhan University - Department of Thoracic Surgery, Wuhan University of Science and Technology - Department of Respiratory and Critical Care Medicine, Hubei University of Medicine - Department of Clinical Oncology, Hubei Provincial Hospital of Traditional Chinese Medicine - Department of Oncology, Huanggang Central Hospital - Department of Oncology, People's Liberation Army - Department of Oncology, Wuhan University - Cancer Center, Wuhan University - Cancer Center, Wuhan University - Cancer Center, Wuhan University - Cancer Center, Huazhong University of Science and Technology - Department of Oncology, Wuhan University - Department of Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 34 (920,641)
Citation 1

Abstract:

Loading...

Risk model; COVID-19; Deterioration; Cancer; Retrospective study

6.

A Novel Prognostic and Immunotherapeutic Predictive Model Based on Cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma

Number of pages: 34 Posted: 18 Nov 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Medical School of Nanjing University - Department of Oncology, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech - Department of Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology
Downloads 24 (1,022,978)

Abstract:

Loading...

lung adenocarcinoma, tumor microenvironment, tumor immune cell score, immunotherapy, biomarker.

7.

Pan-Cancer Indicators of Long-Term Survival Benefits After Immune Checkpoint Inhibitor Therapy

Number of pages: 80 Posted: 03 Mar 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology
Downloads 21 (1,057,985)
Citation 2

Abstract:

Loading...

pan-cancer, long-term survival, immune checkpoint inhibitor, machine learning, predictive analysis, immunotherapy, iLSPS, long-term survival predictive score of immunotherapy